Skip to main content
JBS logo

JBS · Jbs N.V.

Track JBS — free
$12.16 +0.26 (+2.18%) At close · Nov 13
Market Cap
$40.00B
Shares
3.29B
Volume · Nov 13 9.4M Avg daily vol (3M) 6.26M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.16 Open$12.24 Day$12.08–12.46 52W close$10.86–18.42 Avg vol 30d7.4M Short int44.3M · 1.3% of shares · 6.3d Short vol66% Last earningsNov 9, 2026 DataJun 2025–Nov 2026 Filing10-Q · Nov 9

Latest documents

2026
Nov 9
Current report 8-K
Flora and Canal Rural Acquisitions Announced

JBS announced agreements to acquire Flora for R$2.968 billion and Canal Rural for R$88.1 million; both transactions are expected to close in December 2026, subject to customary closing conditions.

Unregistered sale of equity, Regulation FD disclosure, Other events
4 source passages
JBS N.V. (“JBS”) (NYSE: JBS; B3: JBSS32) announced today the acquisition of 100% of Flora, a Brazilian consumer products company owned by J&F Group, JBS’s controlling shareholder, in a transaction valued at US$542 million. JBS S.A. has agreed to acquire Flora for R$2.968 billion, subject to certain adjustments (the “Flora Purchase Price”). JBS S.A. has agreed to acquire Canal Rural for R$88.1 million, subject to certain adjustments (the “Canal Rural Purchase Price”). The Transactions are expected to close in December 2026, subject to customary closing conditions, unless otherwise agreed by the parties. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises as profit and EBITDA fall

JBS N.V. reported nine-month net revenue of US$68.2 billion, but net income fell to US$334.3 million and Adjusted EBITDA to US$3.7 billion.

Revenue $22.74B ▲ 0.6% Net income $164.43M ▼ 71.7% Diluted EPS $0.15 ▼ 71.2%
Read from the MD&A section
3 source passages
Our net revenue was US$68.2 billion and US$63.1 billion for the nine-month periods ended September 30, 2026 and 2025, respectively. We recorded a net income of US$334.3 million and US$1.8 billion for the nine-month periods ended September 30, 2026 and 2025, respectively. Our Adjusted EBITDA was US$3.7 billion and US$5.1 billion for the nine-month periods ended September 30, 2026 and 2025, respectively. Open the document at this passage
Nov 9
Current report 8-K
EBITDA falls 36% as net leverage rises to 3.54x

JBS N.V. reported 3Q26 net sales of $22.7 billion, up 1% from prior year, while IFRS adjusted EBITDA fell 36% to $1,181 million and EPS was $0.15. Net leverage rose to 3.54x, and free cash flow was negative US$167 million.

Financial results
6 source passages
JBS N.V. (NYSE: JBS; B3: JBSS32), announces today its 3Q26 results. •Net Sales of $22.7 billion, up 1% from prior year •IFRS Adjusted EBITDA of $1,181 million, down 36% from prior year •EPS of $0.15, vs. $0.52 from prior year Free cash flow was negative US$167 million in 3Q26, with a US$551 million decrease year-over-year, explained by (i) a US$653 million decline in Adjusted EBITDA and (ii) higher working capital consumption in Brazil, particularly inventories. Net leverage ended the quarter at 3.54x. Open the document at this passage
Oct 16
Registration statement F-4
Registration statement

JBS N.V. is offering to exchange US$1,500,000,000 of 5.625% Senior Notes due 2037 and US$1,000,000,000 of 6.400% Senior Notes due 2057 for registered notes of the same series, originally issued on April 13, 2026.

Read from the first part of this long document
Sep 15
Current report 8-K
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$9.01B
Trailing 12 months
Net income (TTM)
$698.06M
Trailing 12 months
Revenue growth YoY
+0.6%
Year over year
Operating margin
28.3%
Trailing 12 months
P / E (TTM)
17.9
Trailing earnings · reciprocal yield 5.6%
FCF yield
-0.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$16.53B
Latest balance sheet
Dividend yield
8.2%
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-7.5%
Trailing year
Short interest
1.3%
Latest settlement · 6.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −13%
below
Price vs 50-day avg −1%
below
RSI (14) 47
neutral
MACD trend Negative
52-week position 17%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −7%
trailing
6-month return −6%
trailing
YTD return −16%
this year
Relative strength −7%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $12 › 200d $14 — 200d above 50d
Institutional flow Accumulating
276 of 277 funds reported for Sep 30 · net +7.6M sh shares · +68 new
Insider flow Distributing
Net -$2.5M over 90 days · 100% sells
Short interest Rising
1.35% of shares out · ▲ +5.0% MoM · 6.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
277 holders — near 2-yr high, broad support
Squeeze score 54
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 36%
annualized · 1-yr
Max drawdown −41%
past year
ATR 4.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 12, 2026
Capital expenditures · 2026 Maintained $2B
Aug 11, 2026 $2B changed to Aug 12, 2026 $2B
Biological assets · 2026 Maintained $850M
Aug 11, 2026 $850M changed to Aug 12, 2026 $850M
Interest expenses · 2026 Maintained $1.3B
Aug 11, 2026 $1.3B changed to Aug 12, 2026 $1.3B
Effective tax rate · 2026 Maintained 25%
Aug 11, 2026 25% changed to Aug 12, 2026 25%
Leasing expenses · 2026 $500M
Previous outlook earlier release · from the Earnings Call filed Mar 26, 2026

Still-open targets the latest release did not restate under the same label.

Capital expenditures (total) · For 2026, and for the purpose of the EBITDA cash flow break-even $2.4B
Expansion CAPEX · For 2026, and for the purpose of the EBITDA cash flow break-even $1.3B
Maintenance CAPEX · For 2026, and for the purpose of the EBITDA cash flow break-even $1.1B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 5 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−13% Bearish
Price vs 50-day avg
−1% Neutral
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
17% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $12 › 200d $14 — 200d above 50d
Institutional flow Accumulating
276 of 277 funds reported for Sep 30 · net +7.6M sh shares · +68 new
Insider flow Distributing
Net -$2.5M over 90 days · 100% sells
Short interest Rising
1.35% of shares out · ▲ +5.0% MoM · 6.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
277 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $11 Now $12 · 17% Range high $18
vs 200-day avg -13% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted Earnings Per Share Attributable to JBS non-GAAP $0.43 Six Months Ended 2026 —
Adjusted EBITDA USGAAP non-GAAP $1.26B 2Q26 —
Adjusted Net income Attributable to JBS non-GAAP $459.6M Six Months Ended 2026 —
Adjusted Operating Income IFRS non-GAAP $790.2M 2Q26 —
GAAP → non-GAAP reconciliation
GAAP Total Adjusted EBITDA 1.43B
-639.1M Depreciation and amortization
= Adjusted Operating Income (IFRS) 790.2M
Adjusted Operating Income USGAAP non-GAAP $865.9M 2Q26 —
Free Cash Flow non-GAAP $36.4M Six Months Ended 2026 —
Gross Debt/Adjusted EBITDA non-GAAP 3.71 2Q26 —
Interest Coverage non-GAAP 5 Last twelve months ended June 30, 2026 —
ROE non-GAAP 13.4% Last twelve months ended June 30, 2026 —
ROIC non-GAAP 13.4% Last twelve months ended June 30, 2026 —
Total Adjusted EBITDA non-GAAP $6.11B Last twelve months ended June 30, 2026 —
Total Net Debt non-GAAP $18.96B 2Q26 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Packaged Foods — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
JBS
Jbs N.V.
this stock
$40.00B -15.7% — — 1.3%
KHC
Kraft Heinz Co
$29.73B +3.5% -0.1% — 8.7%
GIS
General Mills Inc
$18.35B -26.2% +4.1% — 7.0%
SJM
J M SMUCKER Co
$14.17B +35.7% +3.7% — 2.9%
MKC
Mccormick & Co Inc
$12.64B -31.1% +1.7% 8.5 6.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
324
% held
13.4%
Reported
276 of 277
Top holder
BNDES Participacoes S.A.
Held Float
View
Held by Funds
Fund positions
60
View
Short & Settlement
Short Interest Rising
Shares short
44.3M
Days to cover
6.3d
Change
+2.1M sh
View
Short Volume
Short vol %
66%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
568
Value
$7.3K
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
34.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$2.5M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 9, 2026
This year
25

JBS announced agreements to acquire Flora for R$2.968 billion and Canal Rural for R$88.1 million; both transactions are expected to close in December 2026, subject to customary closing conditions.

View
Proposed Sales
Value
$2.5M
Shares
183.5K
Filed
Aug 21, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
JBS Enters Personal Care Market w…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
JBS -2.6% -6.7% -6.3% -2.6% -15.7%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -5.2% -5.5% -6.8% -2.5% -26.3%

Capital returns

Latest dividend
$1.00 / share · ex May 18, 2026
Paid (TTM)
$1.00 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1791942 CUSIP N4732M103 13F (30d) 235 filings 225 filers Visit website Investor relations